
Roche reports final overall survival outcomes from breast cancer treatment trial
Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta (pertuzumab) with Herceptin (trastuzumab) and chemotherapy for treating breast cancer. The randomised APHINITY trial assessed the …